The Use of Pro-Angiogenic and/or Pro-Hypoxic miRNAs as Tools to Monitor Patients with Diffuse Gliomas

IDH (isocitrate dehydrogenase) mutation, hypoxia, and neo-angiogenesis, three hallmarks of diffuse gliomas, modulate the expression of small non-coding RNAs (miRNA). In this paper, we tested whether pro-angiogenic and/or pro-hypoxic miRNAs could be used to monitor patients with glioma. The miRNAs we...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2022-05, Vol.23 (11), p.6042
Main Authors: Levallet, Guénaëlle, Dubois, Fatéméh, Leclerc, Arthur, Petit, Edwige, Bekaert, Lien, Faisant, Maxime, Creveuil, Christian, Emery, Evelyne, Zalcman, Gérard, Lechapt-Zalcman, Emmanuèle
Format: Article
Language:English
Subjects:
Angiogenesis
Biochemistry, Molecular Biology
Brain cancer
Brain tumors
Cancer
Cell growth
Classification
Dehydrogenases
Genomics
Glioma
Histology
Hypoxia
Isocitrate dehydrogenase
Life Sciences
Medical prognosis
MicroRNAs
miRNA
Morphology
Multivariate analysis
Mutation
Neurobiology
Neurons and Cognition
Paraffins
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:IDH (isocitrate dehydrogenase) mutation, hypoxia, and neo-angiogenesis, three hallmarks of diffuse gliomas, modulate the expression of small non-coding RNAs (miRNA). In this paper, we tested whether pro-angiogenic and/or pro-hypoxic miRNAs could be used to monitor patients with glioma. The miRNAs were extracted from tumoral surgical specimens embedded in the paraffin of 97 patients with diffuse gliomas and, for 7 patients, from a blood sample too. The expression of 10 pro-angiogenic and/or pro-hypoxic miRNAs was assayed by qRT-PCR and normalized to the miRNA expression of non-tumoral brain tissues. We confirmed in vitro that IDH in hypoxia (1% O , 24 h) alters pro-angiogenic and/or pro-hypoxic miRNA expression in HBT-14 (U-87 MG) cells. Then, we reported that the expression of these miRNAs is (i) strongly affected in patients with glioma compared to that in a non-tumoral brain; (ii) correlated with the histology/grade of glioma according to the 2016 WHO classification; and (iii) predicts the overall and/or progression-free survival of patients with glioma in univariate but not in a multivariate analysis after adjusting for sex, age at diagnosis, and WHO classification. Finally, the expression of miRNAs was found to be the same between the plasma and glial tumor of the same patient. This study highlights a panel of seven pro-angiogenic and/or pro-hypoxic miRNAs as a potential tool for monitoring patients with glioma.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms23116042